Edmond DE Rothschild Holding S.A. Sells 77,582 Shares of Boston Scientific Co. (NYSE:BSX)

Edmond DE Rothschild Holding S.A. lessened its holdings in Boston Scientific Co. (NYSE:BSX) by 34.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 148,580 shares of the medical equipment provider’s stock after selling 77,582 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Boston Scientific were worth $13,271,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BSX. Axiom Investors LLC DE boosted its position in Boston Scientific by 208.2% during the 4th quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider’s stock valued at $335,167,000 after acquiring an additional 2,535,007 shares in the last quarter. AIA Group Ltd boosted its position in Boston Scientific by 2,067.2% during the fourth quarter. AIA Group Ltd now owns 96,312 shares of the medical equipment provider’s stock valued at $8,603,000 after purchasing an additional 91,868 shares in the last quarter. Wellington Management Group LLP grew its stake in Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Boston Scientific by 10.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 239,740 shares of the medical equipment provider’s stock worth $21,414,000 after purchasing an additional 23,605 shares in the last quarter. Finally, Physician Wealth Advisors Inc. purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $89,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Barclays upped their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Argus set a $130.00 price objective on Boston Scientific in a research report on Tuesday, February 18th. Stifel Nicolaus upped their target price on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Finally, JPMorgan Chase & Co. raised their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $108.91.

Insider Activity

In related news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the sale, the chief financial officer now owns 225,808 shares of the company’s stock, valued at approximately $23,764,033.92. This trade represents a 22.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now owns 28,454 shares of the company’s stock, valued at $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock worth $14,319,269 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.5 %

Shares of BSX stock opened at $99.29 on Monday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The stock has a 50 day moving average of $102.16 and a 200 day moving average of $93.18. The stock has a market cap of $146.86 billion, a P/E ratio of 79.43, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.